Chuan-Huizi Chen Selected Research

Neoplasms (Cancer)

1/2023	Design, synthesis, and anti-triple negative breast cancer activity of novel Toosendanin derivatives.
1/2022	YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer.
1/2022	A feedforward circuit between KLF5 and lncRNA KPRT4 contributes to basal-like breast cancer.
10/2021	Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer.
1/2020	Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis.
1/2020	Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
1/2019	Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
1/2017	Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
1/2017	Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chuan-Huizi Chen Research Topics

Disease

9	Neoplasms (Cancer) 01/2023 - 01/2017
7	Breast Neoplasms (Breast Cancer) 12/2023 - 01/2019
3	Triple Negative Breast Neoplasms 01/2023 - 01/2020
1	Carcinoma (Carcinomatosis) 10/2021

Drug/Important Bio-Agent (IBA)

2	Transcription Factors (Transcription Factor)IBA 01/2022 - 01/2019
2	Long Noncoding RNAIBA 01/2022 - 01/2021
2	Factor V (Coagulation Factor V)IBA 10/2021 - 01/2019
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 01/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 01/2017
2	olaparibIBA 01/2017 - 01/2017
1	AminesIBA 12/2023
1	PENTAIBA 12/2023
1	SiliconIBA 12/2023
1	GlycosidesIBA 01/2023
1	toosendaninIBA 01/2023
1	acteinIBA 01/2023
1	TriterpenesIBA 01/2023
1	Keratin-16 (Keratin 16)IBA 01/2022
1	AntigensIBA 01/2022
1	polypeptide 3 90kDa ribosomal protein S6 kinaseIBA 01/2022
1	Antisense OligonucleotidesIBA 01/2022
1	Kruppel-Like Transcription Factors (Kruppel-Like Factors)IBA 01/2022
1	Y-Box-Binding Protein 1IBA 01/2022
1	human PRMT2 proteinIBA 10/2021
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 10/2021
1	Mifepristone (RU 486)FDA Link 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Temozolomide (Temodar)FDA LinkGeneric 01/2017
1	simmiparibIBA 01/2017
1	Poly Adenosine Diphosphate RiboseIBA 01/2017

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2017